Physician profile
Wesley Chou
NPI 1841294717
$26,673.86
in general payments reported to CMS, 2019-2025
71 companies · $2,986 in 2025
The $2,986 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,431 · 2020: $3,476 · 2021: $4,704 · 2022: $4,647 · 2023: $4,749 · 2024: $3,681 · 2025: $2,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $385 · Travel and Lodging: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,765.25 |
| Education | $384.86 |
| Travel and Lodging | $266.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,781.60 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $1,949.20 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Abbvie INC. | $1,412.45 | 2019-2025 | Ubrelvy, Duopa, Qulipta |
| Amgen INC. | $1,366.31 | 2019-2023 | Aimovig |
| Neurocrine Biosciences, INC. | $1,271.52 | 2019-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $1,152.67 | 2019-2025 | |
| Pfizer INC. | $1,103.83 | 2019-2025 | |
| Mdd US Operations, LLC | $1,023.36 | 2020-2025 | Gocovri, Gocovri |
| Emd Serono, INC. | $926.41 | 2019-2025 | Mavenclad, Mavenclad |
| Lilly USA, LLC | $819.33 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Lundbeck LLC | $674.94 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $668.02 | 2019-2024 | Ultomiris, Soliris |
| Neurelis, INC. | $662.38 | 2020-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $655.69 | 2019-2025 | Xywav, Epidiolex |
| Celgene Corporation | $652.26 | 2021-2025 | Zeposia |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.